The Effect of Succinylated Gelatin on the Blood Viscosity and Oxygen Delivery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Xia Feng, MD. Ph.D.
- Phone Number: 13688877856
- Email: fengxia@mail.sysu.edu.cn
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- Recruiting
- The First Affiliated Hospital of Sun Yat-sen University
-
Contact:
- Xia Feng, MD. Ph.D.
- Phone Number: 13688877856
- Email: fengxia@mail.sysu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients between the ages of 18 years and 60 years
- ASA physical status I and II
- surgical procedures requiring general anesthesia with continuous CVP and arterial pressure monitoring
Exclusion Criteria:
- Patients younger than 16 y or older than 60 y
- Body Mass Index (BMI) <18 or >30
- Allergy to any of the drugs used
- Severe cardiovascular dysfunction
- Patient refusal
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Ringer's lactate solution
Infusion of Ringer's lactate solution (10ml/kg) in the control group
|
|
|
Active Comparator: Succinylated gelatin
Infusion of Succinylated gelatin (10ml/kg) in the test group
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The patient's arterial blood viscosity (mpa.s) as tested by viscometer
Time Frame: up to 5 months (after the infusion of succinylated gelatin )
|
up to 5 months (after the infusion of succinylated gelatin )
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The patient's oxygen delivery index (DO2I) as calculated by Vigileo
Time Frame: up to 5 months (after the infusion of succinylated gelatin )
|
up to 5 months (after the infusion of succinylated gelatin )
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 2015[22]
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.